natgillin/translations-raw huggingface dataset:
In addition, fewer liver and blood-related problems occur with Rubraca than with other existing treatments for these patients. 
Poleg tega se pri zdravilu Rubraca pojavlja manj težav z jetri in krvjo kot pri drugih obstoječih zdravljenjih za te bolnice.
Of the 79 patients whose disease had responded in the past to platinumbased medicines, 65% (51 patients) had a response to treatment with Rubraca and the response lasted on average 294 days (around 10 months). 
Od 79 bolnic, katerih bolezen se je v preteklosti odzvala na zdravila na osnovi platine, se je 65 % (51 bolnic) odzvalo na zdravljenje z zdravilom Rubraca, odziv pa je trajal povprečno 294 dni (približno 10 mesecev).
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rubraca have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Rubraca upoštevati zdravstveni delavci in bolnice, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
What is Rubraca and what is it used for? 
Kaj je zdravilo Rubraca in za kaj se uporablja?
The company will also provide further data on maintenance treatment, including data on how long patients survived with Rubraca. 
Podjetje bo zagotovilo tudi dodatne podatke o vzdrževalnem zdravljenju, vključno s podatki o času preživetja bolnic, ki prejemajo zdravilo Rubraca.
What benefits of Rubraca have been shown in studies? 
Kakšne koristi zdravila Rubraca so se pokazale v študijah?
As for all medicines, data on the use of Rubraca are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Rubraca stalno spremljajo.
Women must not breastfeed during treatment with Rubraca and for at least 2 weeks after treatment. 
Ženske med zdravljenjem z zdravilom Rubraca in še vsaj dva tedna po zdravljenju ne smejo dojiti.
Rubraca has been given ‘conditional authorisation'. 
Zdravilo Rubraca je pridobilo „pogojno dovoljenje za promet“.
For such patients, tests for a genetic mutation (BRCA mutation) should be carried out first to see if Rubraca is likely to work for them. 
Pri teh bolnicah je treba najprej opraviti testiranje za gensko mutacijo (mutacija v genu BRCA), da se ugotovi, ali je verjetno, da bo zdravilo Rubraca zanje primerno.
The most common side effects with Rubraca (which may affect more than 1 in 5 people) are tiredness or weakness, nausea (feeling sick), increased levels of creatinine (which may indicate kidney problems) and liver enzymes in the blood (which may indicate liver damage), vomiting, anaemia (low red blood cell counts), decreased appetite, dysgeusia (taste disturbances), diarrhoea, thrombocytopenia (low levels of platelets) and abdominal pain (belly ache). 
Najpogostejši neželeni učinki zdravila Rubraca (ki se lahko pojavijo pri več kot 1 od 5 bolnic) so utrujenost ali oslabelost, navzeja (siljenje na bruhanje), zvišane ravni kreatinina (kar lahko kaže na težave z ledvicami) in jetrnih encimov v krvi (kar lahko kaže na poškodbo jeter), bruhanje, anemija (nizko število rdečih krvnih celic), zmanjšan tek, disgevzija (spremembe v okušanju hrane), driska, trombocitopenija (nizko število krvnih ploščic) ter bolečine v trebuhu.
For more information about using Rubraca, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Rubraca glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Side effects reported with Rubraca are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Rubraca, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnic.
It can also be used if the patient's cancer has returned or is worsening after two treatments with platinum-based medicines and they can no longer have these medicines. 
Uporablja se lahko tudi, če se je rak pri bolnici ponovil ali poslabšal po dveh zdravljenjih z zdravili na osnovi platine in teh zdravil ne more več uporabljati.
Rubraca can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the treatment of cancer. 
Predpisovanje in izdaja zdravila Rubraca je le na recept, zdravljenje z njim pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem raka.
In normal cells there is an alternative mechanism for repairing DNA but this alternative mechanism does not work properly in cancer cells with mutations in the BRCA genes. 
V normalnih celicah obstaja alternativni mehanizem popravljanja DNK, ki pa v rakavih celicah z mutacijami v genu BRCA ne deluje pravilno.
Other information about Rubraca 
Druge informacije o zdravilu Rubraca
What are the risks associated with Rubraca? 
Kakšna tveganja so povezana z zdravilom Rubraca?
Two other studies looked at 106 patients with ovarian cancer and BRCA mutation whose cancer had come back following at least 2 previous cancer treatments, including in many cases treatment with platinum-based medicines. 
V drugih dveh študijah so proučevali 106 bolnic z rakom jajčnikov in mutacijo v genu BRCA, pri katerih se je rak po vsaj dveh predhodnih zdravljenjih ponovil, v številnih primerih tudi po zdravljenju z zdravili na osnovi platine.
The active substance in Rubraca, rucaparib, blocks the activity of a family of proteins called poly(ADPribose) polymerases (PARPs) that help to repair damaged DNA in cells (both normal and cancer cells). 
Učinkovina v zdravilu Rubraca, rukaparib, zavira aktivnost družine beljakovin, imenovanih poli (ADPriboza) polimeraze (PARP), ki pomagajo popravljati poškodovano DNK v (normalnih in rakavih) celicah.
What information is still awaited for Rubraca? 
Katere informacije o zdravilu Rubraca še pričakujemo?
proteins are blocked, the damaged DNA in these cancer cells cannot be repaired, and, as a result, the cancer cells die. 
Z zaviranjem beljakovin PARP se poškodovana DNK v teh rakavih celicah torej ne more popraviti in zato rakave celice odmrejo.
Patients given Rubraca lived for 11 months without the disease coming back or getting worse compared with 5 months in patients given placebo (a dummy treatment). 
Bolnice, ki so prejemale zdravilo Rubraca, so živele 11 mesecev brez ponovnega pojava ali poslabšanja bolezni, tiste, ki so prejemale placebo (zdravilo brez učinkovine), pa pet mesecev.
Since Rubraca has been given conditional authorisation, the company that markets the medicine will provide the results from an ongoing study comparing Rubraca with chemotherapy (another cancer medicine) in patients with high-grade epithelial cancer of the ovary, of the fallopian tubes or of the peritoneum with BRCA mutation whose cancer has come back after chemotherapy treatments. 
Ker je zdravilo Rubraca pridobilo pogojno dovoljenje za promet, bo podjetje, ki ga trži, zagotovilo rezultate iz študije, ki poteka in v kateri primerjajo zdravilo Rubraca s kemoterapijo (drugim zdravilom za zdravljenje raka) pri bolnicah z epitelijskim rakom jajčnikov, jajcevodov ali peritonealnega raka visoke stonje z mutacijo v genu BRCA, pri katerih se je rak po zdravljenju s kemoterapijo ponovil.
Rubraca was also beneficial to patients whose cancer had come back after 2 previous cancer treatments, although these benefits have only been shown in patients with a BRCA mutation. 
Zdravilo Rubraca je koristilo tudi bolnicam, katerih rak se je ponovil po dveh predhodnih zdravljenjih raka, vendar so se ti učinki pokazali le pri bolnicah z mutacijo v genu BRCA.
For maintenance treatment, Rubraca should be used no later than 8 weeks after the patient has finished their treatment with platinum-based medicine. 
Pri vzdrževalnem zdravljenju je treba zdravilo Rubraca uporabiti najpozneje osem tednov po končanem zdravljenju z zdravilom na osnovi platine.
Rubraca as maintenance treatment was investigated in a study of 564 patients with ovarian cancer which had cleared (partially or completely) after treatment with platinum-based cancer medicines. 
Zdravilo Rubraca so kot vzdrževalno zdravljenje proučevali v študiji s 564 bolnicami z rakom jajčnikov, ki je (delno ali v celoti) izginil po zdravljenju z zdravili za zdravljenje raka na osnovi platine.
How is Rubraca used? 
Kako se zdravilo Rubraca uporablja?
It can be used as maintenance treatment in patients whose recurring cancer has cleared (partially or completely) after treatment with platinum-based cancer medicines. 
Zdravilo Rubraca se lahko uporablja za vzdrževalno zdravljenje pri bolnicah, pri katerih je ponovljeni rak (delno ali v celoti) izginil po zdravljenju z zdravili za zdravljenje raka na osnovi platine.
This benefit was seen in patients with or without the BRCA mutation. 
Ta učinek je bil viden pri bolnicah z mutacijo v genu BRCA ali brez nje.
Rubraca is a cancer medicine for treating high-grade cancers of the ovary, fallopian tubes (the tubes connecting ovaries to the uterus) and the peritoneum (the membrane lining the abdomen). 
Rubraca je zdravilo za zdravljenje raka jajčnikov, jajcevodov (cevastih organov, ki povezujejo jajčnike z maternico) in peritonealnega (mrena v trebušni votlini) raka visoke stopnje.
This benefit with Rubraca was seen in patients with or without the BRCA mutation. 
Ta učinek zdravila Rubraca je bil viden pri bolnicah z mutacijo v genu BRCA ali brez nje.
How does Rubraca work? 
Kako zdravilo Rubraca deluje?
Treatment may be interrupted and doses may be reduced in patients who have certain side effects. 
Pri bolnicah, ki imajo določene neželene učinke, bo morda treba zdravljenje prekiniti ali zmanjšati odmerek.
For the full list of side effects of Rubraca, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Rubraca, glejte navodilo za uporabo.
The recommended dose of Rubraca is 600 mg twice a day. 
Zdravilo Rubraca je na voljo v obliki tablet po 200, 250 in 300 mg. Priporočeni odmerek zdravila Rubraca je 600 mg dvakrat na dan. Zdravljenje je treba nadaljevati, dokler rak napreduje ali se pri bolnici pojavijo nesprejemljivi neželeni učinki.
Rubraca has been shown to delay worsening or return of the disease in patients whose cancer had cleared partially or completely after treatment with platinum-based medicines. 
Pri bolnicah, pri katerih je rak po zdravljenju z zdravili na osnovi platine delno ali v celoti izginil, se je pokazalo, da zdravilo Rubraca upočasni poslabšanje ali ponovitev bolezni.
It is available as tablets (400 and 800 mg). 
Na voljo je v tabletah (400 in 800 mg).
The European Commission granted a marketing authorisation valid throughout the European Union for Renagel on 28 January 2000. 
Evropska komisija je dovoljenje za promet z zdravilom Renagel, veljavno po vsej Evropski uniji, izdala 28. januarja 2000.
The full EPAR for Renagel can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Renagel je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This leads to hyperphosphataemia, which, in the long term, can cause complications such as heart and bone disease. 
To povzroča hiperfosfatemijo, ki lahko dolgoročno vodi do zapletov, na primer do bolezni srca in okostja.
What measures are being taken to ensure the safe and effective use of Renagel? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Renagel?
This is a summary of the European public assessment report (EPAR) for Renagel. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Renagel.
In the third, there was an average fall of 0.71 mmol/l over 44 weeks. 
V tretji študiji je bilo v 44 tednih ugotovljeno povprečno znižanje za 0,71 mmol/l.
In all of the studies, the main measure of effectiveness was the change in blood phosphate levels between the start and the end of treatment. 
V vseh študijah je bilo glavno merilo učinkovitosti sprememba ravni fosfatov v krvi od začetka do konca zdravljenja.
Patients should take Renagel tablets whole with meals and stick to their prescribed diets. 
Bolniki morajo tablete zdravila jemati cele ob obroku in se držati predpisane diete.
Other information about Renagel 
Druge informacije o zdravilu Renagel
For more information about treatment with Renagel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Renagel preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
A risk management plan has been developed to ensure that Renagel is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Renagel je bil pripravljen načrt obvladovanja tveganj.
Patients with long-term kidney disease cannot eliminate phosphate from their bodies. 
Bolniki z dolgotrajno boleznijo ledvic iz telesa ne morejo izločati fosfatov.
When taken with meals, it attaches to phosphate from food within the gut, preventing it from being absorbed into the body. 
Če se zdravilo jemlje ob obrokih, se v črevesju veže na fosfate iz hrane, s čimer preprečuje njihovo absorpcijo v telo.
Renagel should be used with other treatments such as calcium or vitamin D supplements to control the development of bone disease. 
Zdravilo Renagel je treba uporabljati skupaj z drugimi načini zdravljenja, na primer z dodatki kalcija in vitamina D za nadzor razvoja obolenja kosti.
In haemodialysis, Renagel has been studied in two short-term studies lasting eight weeks and one longer study lasting 44 weeks. 
Pri hemodializi so zdravilo Renagel proučili v dveh kratkotrajnih študijah (8 tednov) in eni daljši študiji (44 tednov).
The recommended starting dose of Renagel depends on the level of phosphate in the blood and ranges from 800 to 1,600 mg three times a day. 
Priporočeni začetni odmerek zdravila Renagel je odvisen od koncentracije fosfatov v krvi in znaša od 800 do 1 600 mg trikrat dnevno.
The longer study looked at the use of Renagel in 192 patients, the majority of whom had taken Renagel in previous studies. 
V daljši študiji so proučevali uporabo zdravila Renagel pri 192 bolnikih, od katerih ga je večina jemala v predhodnih študijah.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Renagel. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The CHMP decided that Renagel's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Renagel večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Renagel, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
The second, which did not compare Renagel with any other medicines, included 172 patients. 
V drugi študiji, v kateri zdravila Renagel niso primerjali z nobenim drugim zdravilom, je sodelovalo 172 bolnikov.
What benefit has Renagel shown during the studies? 
Kakšne koristi je zdravilo Renagel izkazalo med raziskavami?
The most common side effects with Renagel (seen in more than 1 patient in 10) are nausea (feeling sick) and vomiting. 
Najpogostejša neželena učinka zdravila Renagel (opažena pri enem bolniku od desetih) sta navzeja (slabost) in bruhanje.
The dose of Renagel should be adjusted to ensure that the blood phosphate level stays below 1.76 mmol/l. 
Odmerek zdravila je treba prilagoditi tako, da koncentracija fosfatov v krvi ostane pod 1,76 mmol/l.
It can be used in patients undergoing haemodialysis (dialysis using a blood filtration machine) or peritoneal dialysis (where fluid is pumped into the abdomen and an internal body membrane filters the blood). 
Lahko se uporablja pri bolnikih, ki prejemajo hemodializo (dializo z uporabo naprave za filtriranje krvi) ali peritonealno dializo (pri čemer se tekočina črpa v trebuh, notranja telesna membrana pa filtrira kri).
In the comparative study of patients undergoing haemodialysis, there was an average fall of 0.65 mmol/l over the eight weeks of Renagel treatment, compared with 0.68 mmol/l when the patients were taking calcium acetate. 
V primerjalni študiji bolnikov, ki so prejemali hemodializo, je bilo povprečno znižanje v osmih tednih zdravljenja z zdravilom Renagel 0,65 mmol/l, medtem ko je bilo znižanje pri bolnikih, ki so prejemali kalcijev acetat, 0,68 mmol/l.
In the study of patients undergoing peritoneal dialysis, the patients receiving Renagel had similar falls in phosphate as the patients receiving calcium acetate (0.52 and 0.58 mmol/l, respectively). 
V študiji z bolniki, ki so prejemali peritonealno dializo, je bilo pri bolnikih, ki so prejemali zdravilo Renagel, ugotovljeno podobno znižanje koncentracije fosfatov kot pri bolnikih, ki so prejemali kalcijev acetat (0,52 oziroma 0,58 mmol/l).
What is the risk associated with Renagel? 
Kakšna tveganja so povezana z zdravilom Renagel?
In peritoneal dialysis, there has been one study comparing Renagel with calcium acetate in 143 patients over 12 weeks. 
Pri peritonealni dializi so v eni študiji zdravilo 12 tednov primerjali s kalcijevim acetatom pri 143 bolnikih.
Why has Renagel been approved? 
Zakaj je bilo zdravilo Renagel odobreno?
The first study compared Renagel with calcium acetate (another phosphate-lowering medicine) in 84 patients. 
V prvi študiji so zdravilo primerjali s kalcijevim acetatom (drugim zdravilom za zniževanje koncentracije fosfatov) pri 84 bolnikih.
Renagel produced a significant decrease in serum phosphate in all of the studies. 
Zdravilo Renagel je v vseh študijah povzročilo bistveno znižanje koncentracije fosfatov v serumu.
For the full list of all side effects reported with Renagel, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Renagel, glejte navodilo za uporabo.
Renagel is a medicine that contains the active substance sevelamer hydrochloride. 
Renagel je zdravilo, ki vsebuje zdravilno učinkovino sevelamerijev hidroklorid.
Renagel is used to control hyperphosphataemia (high blood phosphate levels) in adults on dialysis (a blood clearance technique used in patients with kidney disease). 
Zdravilo Renagel se uporablja za uravnavanje hiperfosfatemije (visoke koncentracije fosfatov v krvi) pri odraslih osebah na dializi (tehniki čiščenja krvi pri bolnikih z obolenjem ledvic).
Renagel sevelamer hydrochloride 
Renagel sevelamerijev hidroklorid
Patients taking Renagel had a similar fall in phosphate levels in the second study. 
Pri bolnikih, ki so jemali zdravilo Renagel, je bilo v drugi študiji ugotovljeno podobno znižanje koncentracije fosfatov.
Renagel must not be used in people with hypophosphataemia (low blood phosphate levels) or with bowel obstruction (a blockage in the gut). 
Zdravila se ne sme uporabljati pri ljudeh s hipofosfatemijo (nizko koncentracijo fosfatov v krvi) ali zaporo črevesa.
How does Renagel work? 
Kako zdravilo Renagel deluje?
What is Renagel? 
Kaj je zdravilo Renagel?
How has Renagel been studied? 
Kako je bilo zdravilo Renagel raziskano?
The active substance in Renagel, sevelamer hydrochloride, is a phosphate binder. 
Zdravilna učinkovina zdravila Renagel je fosfatni vezalec sevelamerijev hidroklorid.
What is Renagel used for? 
Za kaj se zdravilo Renagel uporablja?
How is Renagel used? 
Kako se zdravilo Renagel uporablja?
List of the names, pharmaceutical forms, strength of the medicinal product, route of administration, marketing authorisation holder in the Member States 
Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila in imetnikov dovoljenj za promet z zdravilom v državah članicah
Pharmaceutical form Route of administration 
Farmacevtska oblika Pot uporabe
Goserelin Novosis 3,6 mg Implantat implant, pre-filled syringe subcutaneous use 
Goserelin Novosis 3,6 mg Implantat implantat, napolnjena injekcijska brizga
50 ml (10 mg/ml) 1 vial 
50 ml (10 mg/ml) 1 viala
Date of opening:____________ 
Datum odprtja:_________________
- The other ingredients are: 
- Druge sestavine so:
Pregnancy and Postpartum During the second and third trimesters of pregnancy: 
Nosečnost in poporodno obdobje Drugo in tretje trimesečje nosečnosti:
It is important to note that at time of the 96-week analysis, 48 % of patients overall remained on study. 
Omeniti je treba, da je bilo v študiji v času analize po 96 tednih v celoti še 48 % bolnikov.
Typically, such reactions have been observed within the first few weeks or months of initiation of CART. 
Take reakcije so navadno opazili v prvih nekaj tednih ali mesecih po uvedbi
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine. 
O neželenih učinkih lahko poročate tudi neposredno na nacionalni center za poročanje, ki je naveden v Prilogi V: S tem, ko poročate o neželenih učinkih, lahko prispevate k zagotovitvi več informacij o varnosti tega zdravila.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom preden vzamete to zdravilo.
Frequency is defined using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000). 
Pogostnost neželenih učinkov je opredeljena v skladu z naslednjim dogovorom: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000).
PHARMACEUTICAL FORM AND CONTENTS Hard capsule 
FARMACEVTSKA OBLIKA IN VSEBINA trda kapsula
Per protocol analysise 
Analiza po protokolu e
Switching to capsules from other formulations is encouraged as soon as patients are able to consistently swallow capsules. 
Prehod z zdravljenja z drugimi formulacijami na zdravljenje s kapsulami je priporočljiv takoj, ko lahko bolniki kapsule zanesljivo pogoltnejo.
Difference estimatee [95% CI] 
Ocenjena razlika [95 % IZ]
Efficacy Outcomes at Week 48a and at Week 96 (Study 045) 
Preglednica 6: Izidi učinkovitosti v 48. tednu in 96. tednu (študija 045)
The rash usually disappears within 2 weeks without any change to your atazanavir treatment. 
Izpuščaj običajno izzveni v 2 tednih brez kakršne koli spremembe zdravljenja z atazanavirjem.
If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose), contact your doctor before taking this medicinal product. 
Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev (npr. laktoze), se pred uporabo tega zdravila posvetujte z zdravnikom.
b Cmin is concentration 24 hours post-dose 
b Cmin je koncentracija 24 ur po uporabi odmerka.
The fluticasone propionate plasma levels increased significantly, whereas the intrinsic cortisol levels decreased by approximately 86% (90% confidence interval 82%89%). 
Plazemske vrednosti flutikazonpropionata so se znatno povečale, intrinzične vrednosti kortizola pa zmanjšale za približno 86% (90% interval zaupanja; 82-89%).
Atazanavir Krka capsules may be used by adults and children 6 years of age and older. 
Kapsule Atazanavir Krka lahko uporabljajo odrasli in otroci, stari 6 let in več.
90 (3 x 30) hard capsules 
90 (3 x 30) trdih kapsul